Compare Enveric Biosciences Inc (ENVB) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs IQIYI Inc - ADR — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while IQIYI Inc - ADR trades at $1.35 (market cap $1.31B). The key difference: IQIYI Inc - ADR is far larger — about 211.3× Enveric Biosciences Inc's market cap, and IQIYI Inc - ADR is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | IQ | |
|---|---|---|
Market Cap | $6.20M | $1.31B |
Sector | Health | Media |
52-Week High | $17.40 | $2.79 |
52-Week Low | $1.27 | $0.96 |
Enterprise Value | $1.30M | $2.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
iQIYI (IQ) trades at $1.33, up 3.1% in 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 revenue of $915.2M, missing expectations, but beat EPS estimates. Valuation ratios show low P/S and P/B, but negative profitability metrics persist. Recent news highlights AI platform growth and leadership changes, with analyst consensus leaning buy.
Outlook: Potential upside exists from AI initiatives and cost controls, but risks include revenue declines, regulatory pressures, and negative cash flow projections. Investors should weigh low valuation against profitability challenges and China market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
